Association of progression-free survival with patient-reported outcomes and survival: Results from a randomised phase 3 trial of panitumumab

S. Siena, M. Peeters, E. Van Cutsem, Y. Humblet, P. Conte, E. Bajetta, D. Comandini, G. Bodoky, G. Van Hazel, T. Salek, M. Wolf, G. Devercelli, M. Woolley, R. G. Amado

Research output: Contribution to journalArticle

Abstract

In a randomised phase 3 trial, panitumumab significantly improved progression-free survival (PFS) in patients with refractory metastatic colorectal cancer (mCRC). This analysis characterises the association of PFS with CRC symptoms, health-related quality of life (HRQoL), and overall survival (OS). CRC symptoms (NCCN/FACT CRC symptom index, FCSI) and HRQoL (EQ-5D) were assessed for 207 panitumumab patients and 184 best supportive care (BSC) patients who had at least one post-baseline patient-reported outcome (PRO) assessment. Patients alive at week 8 were included in the PRO and OS analyses and categorised by their week 8 progression status as follows: no progressive disease (no PD; best response of at least stable disease) vs progressive disease (PD). Standard imputation methods were used to assign missing values. Significantly more patients were progression free at weeks 8-24 with panitumumab vs BSC. After excluding responders, a significant difference in PFS remained favouring panitumumab (HR=0.63, 95% CI=0.52-0.77; P

Original languageEnglish
Pages (from-to)1469-1474
Number of pages6
JournalBritish Journal of Cancer
Volume97
Issue number11
DOIs
Publication statusPublished - Dec 3 2007

Keywords

  • Disease progression
  • Improvement
  • Panitumumab
  • Patient-reported outcomes
  • Quality of life
  • Symptom

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Association of progression-free survival with patient-reported outcomes and survival: Results from a randomised phase 3 trial of panitumumab'. Together they form a unique fingerprint.

  • Cite this

    Siena, S., Peeters, M., Van Cutsem, E., Humblet, Y., Conte, P., Bajetta, E., Comandini, D., Bodoky, G., Van Hazel, G., Salek, T., Wolf, M., Devercelli, G., Woolley, M., & Amado, R. G. (2007). Association of progression-free survival with patient-reported outcomes and survival: Results from a randomised phase 3 trial of panitumumab. British Journal of Cancer, 97(11), 1469-1474. https://doi.org/10.1038/sj.bjc.6604053